CLOVES syndrome
Therapeutic area
Dermatology
Rare disease
Yes
- Definition
- A syndromic disease characterized by Congenital Lipomatous Overgrowth, progressive, complex and mixed truncal Vascular malformations, Epidermal nevi, and Skeletal anomaly.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- CLOVES syndrome
- Therapeutic area
- Dermatology
- CLOVES syndrome
- CLOVE syndrome, somatic
- CLOVES syndrome
- congenital lipomatous overgrowth, vascular malformations, and epidermal nevi
- congenital lipomatous overgrowth-vascular malformation-epidermal nevi-skeletal anomaly syndrome
- congenital lipomatous overgrowth-vascular malformation-epidermal nevi-spinal anomaly syndrome
- congenital lipomatous overgrowth - vascular malformation - epidermal nevi
- Severity
- Severe
- Developmental
- Genetic
- Hereditary
- Syndromic
- Dermatology
- Oncology
- MONDO ID
- MONDO:0013038
- Parent condition
- MONDO:0002254
Related records
Broader conditions (26)
- Benign neoplasm
- Benign neoplasm of skin
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Disorder of development or morphogenesis
- Hereditary disease
- Hereditary skin disorder
- Human disease
- Integumentary system benign neoplasm
- Integumentary system disorder
- Melanocytic neoplasm
- Melanocytic nevus
- Melanocytic skin neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Neurocristopathy
Trials (6)
- A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
- A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome
- Identification of Biomarkers for Patients with Vascular Anomalies
- Lymphatic Anomalies Registry for the Assessment of Outcome Data
- National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
- Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery